Increased expression of methionine sulfoxide reductases B3 is associated with poor prognosis in gastric cancer
Increased expression of methionine sulfoxide reductases B3 is associated with poor prognosis in gastric cancer
复制标题
DOI：
10.3892/ol.2019.10318
复制
发表时间：
2019-07-01
期刊：
影响因子：
2.9
通讯作者：
Wu, Jianqiang
中科院分区：
文献类型：
--
作者：
Ma, Xiaoming;Wang, Jian;Wu, Jianqiang
本研究旨在探讨甲硫氨酸亚砜还原酶B3 （MSRB3）在胃癌（GC）中的表达及其临床意义。收集90例胃癌患者标本，采用免疫组化染色法检测MSRB3蛋白表达。随后研究了MSRB3蛋白表达与胃癌患者临床病理特征及预后的关系。结果表明，GC组织样品中MSRB3蛋白的表达显著高于配对相邻正常组织（P=0.017）。90例胃癌中，64例（71.1%）表现出较高的MSRB3表达。此外，估计MSRB3对GC患者的诊断价值，敏感性为71.1%，特异性为46.7%。然而，MSRB3的表达与胃癌患者的临床病理特征无关。Kaplan-Meier分析显示，MSRB3高表达患者的总生存期（OS）明显短于低表达患者（P=0.040）。单因素Cox回归分析显示，肿瘤最大直径、浸润深度、淋巴结转移、肿瘤-淋巴结-转移（TNM）分期及MSRB3表达与肿瘤生存时间显著相关。多因素Cox回归分析显示，MSRB3是GC患者OS时间的独立预测因素（P=0.049）。此外，使用癌症基因组图谱（TCGA）数据库进行分析验证了这些结果。Kaplan-Meier分析显示，442例GC患者中MSRB3 mRNA的高表达与较差的OS时间相关（P=0.004）。TCGA数据的单因素分析显示，年龄、浸润深度、淋巴结转移、远处转移、TNM分期和MSRB3表达与OS时间显著相关；然而，性别和组织学分化与OS时间无关。多因素分析显示MSRB3是胃癌患者的独立预后因素（P=0.001）。总之，这些结果表明MSBR3在胃癌患者中表达上调，这表明MSBR3可能作为潜在的预后生物标志物。
The present study aimed to investigate the expression of methionine sulfoxide reductases B3 (MSRB3) in gastric cancer (GC) and its clinical significance. A total of 90 specimens from patients with GC were collected to evaluate MSRB3 protein expression by immunohistochemical staining. The associations between MSRB3 protein expression, clinicopathological characteristics and prognosis of patients with GC were subsequently investigated. The results demonstrated that MSRB3 protein expression in GC tissues samples was significantly higher compared with that in paired adjacent normal tissues (P=0.017). Among the 90 GC cases, 64 (71.1%) exhibited higher MSRB3 expression. In addition, the diagnostic value of MSRB3 for patients with GC was estimated with a sensitivity of 71.1% and a specificity of 46.7%. However, MSRB3 expression was not associated with clinicopathological characteristics of patients with GC. Kaplan-Meier analysis indicated that patients with high MSRB3 expression had significantly shorter overall survival (OS) times compared with those with low expression (P=0.040). Univariate Cox regression analysis indicated that maximum tumor diameter, depth of invasion, lymph node metastasis, Tumor-Node-Metastasis (TNM) stage and MSRB3 expression were significantly associated with OS time. Multivariate Cox regression analysis indicated that MSRB3 was an independent predicting factor for the OS time of patients with GC (P=0.049). In addition, analysis using The Cancer Genome Atlas (TCGA) database validated these results. Kaplan-Meier analysis revealed that higher MSRB3 mRNA expression was associated with poorer OS time in 442 patients with GC (P=0.004). Univariate analysis of the TCGA data indicated that age, depth of invasion, lymph node metastasis, distant metastasis, TNM stage and MSRB3 expression were significantly associated with OS time; however, sex and histological differentiation were not associated with OS time. Multivariate analysis demonstrated that MSRB3 was an independent prognostic factor in patients with GC (P=0.001). In conclusion, these results demonstrated that MSRB3 expression was upregulated in patients GC, which suggests that MSBR3 may serve as a potential prognostic biomarker.